KLK10 and adenocarcinoma: Kallikreins are being investigated as potential serum markers for adenocarcinomas such as prostate (KLK2), breast (KLK10, 12, 13) and ovary (KLK6, 8, 10, 11) (Diamandis and Yousef, 2002) (Figure 2C).